MX2018010788A - Composicion oftalmologica. - Google Patents
Composicion oftalmologica.Info
- Publication number
- MX2018010788A MX2018010788A MX2018010788A MX2018010788A MX2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- hyaluronic acid
- ophthalmological composition
- ectoine
- derivative
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 3
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract 2
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición oftalmológica con alta viscosidad. La composición de acuerdo con la invención contiene o consta de ácido hialurónico o de un derivado de ácido hialurónico como, por ejemplo, una sal oftalmológicamente aceptable de ácido hialurónico así como ectoína o un derivado de ectoína oftalmológicamente aceptable. La composición está caracterizada además porque no comprende ningún otro ingrediente farmacéuticamente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102016203696.3A DE102016203696A1 (de) | 2016-03-07 | 2016-03-07 | Ophthalmologische Zusammensetzung |
| PCT/EP2017/055338 WO2017153415A1 (de) | 2016-03-07 | 2017-03-07 | Ophthalmologische zusammensetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010788A true MX2018010788A (es) | 2019-01-14 |
| MX382534B MX382534B (es) | 2025-03-13 |
Family
ID=58264510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010788A MX382534B (es) | 2016-03-07 | 2017-03-07 | Composicion oftalmologica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190099441A1 (es) |
| EP (1) | EP3426226B1 (es) |
| JP (1) | JP2019511494A (es) |
| KR (1) | KR20180117635A (es) |
| CN (1) | CN108778250A (es) |
| AU (1) | AU2017231697B2 (es) |
| BR (1) | BR112018067995B1 (es) |
| DE (1) | DE102016203696A1 (es) |
| ES (1) | ES2922821T3 (es) |
| LT (1) | LT3426226T (es) |
| MX (1) | MX382534B (es) |
| PT (1) | PT3426226T (es) |
| RU (1) | RU2749723C2 (es) |
| WO (1) | WO2017153415A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016203696A1 (de) | 2016-03-07 | 2017-09-07 | Ursapharm Arzneimittel Gmbh | Ophthalmologische Zusammensetzung |
| CN109771427A (zh) * | 2019-01-30 | 2019-05-21 | 上海克琴科技有限公司 | 一种通过提高依克多因光学纯度来增强其安全性和抗炎抗过敏活性的方法 |
| EP3827818A1 (en) * | 2019-11-26 | 2021-06-02 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
| CN110974830A (zh) * | 2019-12-26 | 2020-04-10 | 华熙生物科技股份有限公司 | 一种用于预防、缓解或治疗皮肤过敏的外用组合物及其用途 |
| CN111518627A (zh) * | 2020-05-09 | 2020-08-11 | 华熙生物科技股份有限公司 | 一种隐形眼镜护理液以及制备方法 |
| DE102020112603A1 (de) * | 2020-05-10 | 2021-11-11 | Bitop Aktiengesellschaft | Kompatible Solute zur Prävention oder Behandlung von SARS-CoV-2-Infektionen |
| CN111467349B (zh) * | 2020-05-14 | 2021-06-01 | 华熙生物科技股份有限公司 | 人工泪液及其制备方法 |
| CN111407774B (zh) * | 2020-05-15 | 2022-03-22 | 华熙生物科技股份有限公司 | 一种眼科用组合物及其制备方法 |
| CN111905094B (zh) * | 2020-06-15 | 2022-08-09 | 华熙生物科技股份有限公司 | 一种眼用组合物及其在制备用于干眼症的药物中的用途 |
| CN112220102B (zh) * | 2020-09-25 | 2022-12-09 | 山东华熙海御生物医药有限公司 | 一种含透明质酸和依克多因的电子烟液及其制备方法 |
| CN112480483B (zh) * | 2020-11-27 | 2022-02-01 | 华熙生物科技股份有限公司 | 一种依克多因-透明质酸复合凝胶的制备方法及所得产品 |
| CN112870455B (zh) * | 2021-02-05 | 2022-05-24 | 华熙生物科技股份有限公司 | 一种含透明质酸的凝胶制剂、制法及其在内窥镜检查中的应用 |
| US12012238B2 (en) * | 2021-05-26 | 2024-06-18 | Bausch + Lomb Ireland Limited | Packaging solutions |
| CN116139067B (zh) * | 2021-11-22 | 2024-03-22 | 华熙生物科技股份有限公司 | 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备 |
| CN114569491B (zh) * | 2022-04-18 | 2023-08-18 | 华熙生物科技股份有限公司 | 一种抑制油脂生成的组合物及其用途 |
| CN115317598A (zh) * | 2022-09-22 | 2022-11-11 | 深圳中科欣扬生物科技有限公司 | 一种用于口腔溃疡的含sod贴剂及其制备方法 |
| CN116024050A (zh) * | 2022-12-14 | 2023-04-28 | 江苏视准医疗器械有限公司 | 一种角膜接触镜保存液组合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4342560A1 (de) | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten |
| JP4540872B2 (ja) * | 2001-04-02 | 2010-09-08 | 株式会社資生堂 | 乾燥による皮膚傷害の抑制剤もしくは修復剤 |
| DE10161110A1 (de) * | 2001-12-12 | 2003-06-26 | Ursapharm Arzneimittel Gmbh | Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| US7160560B2 (en) * | 2003-10-23 | 2007-01-09 | L'oreal S.A. | Skin-care composition |
| DE102007052380A1 (de) | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
| CN101491526A (zh) * | 2009-03-03 | 2009-07-29 | 山东大学 | 四氢嘧啶在制备治疗关节炎的药物中的应用 |
| DE102014007423A1 (de) * | 2014-05-22 | 2015-11-26 | Bitop Ag | Zusammensetzung zur Behandlung des Auges |
| DE102016203696A1 (de) | 2016-03-07 | 2017-09-07 | Ursapharm Arzneimittel Gmbh | Ophthalmologische Zusammensetzung |
-
2016
- 2016-03-07 DE DE102016203696.3A patent/DE102016203696A1/de not_active Withdrawn
-
2017
- 2017-03-07 US US16/082,791 patent/US20190099441A1/en not_active Abandoned
- 2017-03-07 MX MX2018010788A patent/MX382534B/es unknown
- 2017-03-07 ES ES17709641T patent/ES2922821T3/es active Active
- 2017-03-07 RU RU2018130713A patent/RU2749723C2/ru active
- 2017-03-07 JP JP2018547451A patent/JP2019511494A/ja not_active Revoked
- 2017-03-07 BR BR112018067995-0A patent/BR112018067995B1/pt active IP Right Grant
- 2017-03-07 LT LTEPPCT/EP2017/055338T patent/LT3426226T/lt unknown
- 2017-03-07 EP EP17709641.9A patent/EP3426226B1/de not_active Revoked
- 2017-03-07 PT PT177096419T patent/PT3426226T/pt unknown
- 2017-03-07 WO PCT/EP2017/055338 patent/WO2017153415A1/de not_active Ceased
- 2017-03-07 CN CN201780015735.3A patent/CN108778250A/zh active Pending
- 2017-03-07 KR KR1020187025990A patent/KR20180117635A/ko not_active Ceased
- 2017-03-07 AU AU2017231697A patent/AU2017231697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190099441A1 (en) | 2019-04-04 |
| RU2749723C2 (ru) | 2021-06-16 |
| DE102016203696A1 (de) | 2017-09-07 |
| CA3015592A1 (en) | 2017-09-14 |
| KR20180117635A (ko) | 2018-10-29 |
| PT3426226T (pt) | 2022-07-20 |
| AU2017231697A1 (en) | 2018-09-13 |
| ES2922821T3 (es) | 2022-09-20 |
| LT3426226T (lt) | 2022-07-25 |
| RU2018130713A (ru) | 2020-04-08 |
| JP2019511494A (ja) | 2019-04-25 |
| MX382534B (es) | 2025-03-13 |
| EP3426226A1 (de) | 2019-01-16 |
| BR112018067995B1 (pt) | 2023-09-26 |
| BR112018067995A2 (pt) | 2019-01-15 |
| RU2018130713A3 (es) | 2020-06-30 |
| WO2017153415A1 (de) | 2017-09-14 |
| AU2017231697B2 (en) | 2022-07-07 |
| EP3426226B1 (de) | 2022-05-04 |
| CN108778250A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382534B (es) | Composicion oftalmologica | |
| EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MY210123A (en) | Tlr7/8 antagonists and uses thereof | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| EP4309735A3 (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| MY180526A (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| MY185491A (en) | Macrocylic pyrimidine derivatives | |
| MY185500A (en) | Macrocylic pyridine derivatives | |
| NZ717825A (en) | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| WO2015152577A3 (ko) | 골 질환 예방 및 치료용 조성물 | |
| MD20160040A2 (ro) | Pidotimod pentru utilizare în tratamentul bolilor asociate cu inflamaţie | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| WO2015181837A3 (en) | Novel compounds as anti-tubercular agents | |
| WO2016027160A3 (en) | Nasal composition comprising mixture of hyaluronic acids and saline solution | |
| MX2021000040A (es) | Formulaciones farmaceuticas estables de oximetazolina. | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| WO2019125166A3 (en) | Hyaluronic acid formulations |